Literature DB >> 1803860

IL-6 receptors and sensitivity to growth inhibition by IL-6 in clones of human breast carcinoma cells.

L Chen1, L M Shulman, M Revel.   

Abstract

Pure recombinant human IL-6 inhibits growth of T47D, MCF-7 and SK-BR-3 human breast carcinoma and OVCAR-3 ovarian carcinoma cells in cultures. Subcloning of the breast ductal carcinoma T47D cells yields clones with high and low sensitivity to the growth inhibitory effect of IL-6. The subclones vary 40 fold in their sensitivity for inhibition of colony formation in sparse cultures and 200 fold for inhibition of thymidine incorporation in subconfluent cultures. Binding studies with 125I-rIL6 show that T47D cells and their subclones, as well as SK-BR-3 and MCF-7 cells, express high-affinity receptors for IL-6. The number and affinity constant of these receptors are comparable to those on lymphocytic and myeloid cells, and show no correlation with the high or low sensitivity phenotype. Proliferation of the breast cancer cells is inhibited by IL-6 in a cell density dependent manner, and is not due to a cytotoxic effect. In addition, IL-6 induces a morphological change with loss of epithelial characteristics and of cell-cell adhesion. Sensitivity to growth inhibition by IL-6 is independent from that of IFN-beta 1, IFN-gamma or TNF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1803860

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  9 in total

Review 1.  The functions of cytokines and their uses in toxicology.

Authors:  J R Foster
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

2.  E-cadherin distribution in interleukin 6-induced cell-cell separation of ductal breast carcinoma cells.

Authors:  I Tamm; I Cardinale; T Kikuchi; J G Krueger
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

3.  Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial-to-mesenchymal transformation in breast cancer cells.

Authors:  P B Sehgal
Journal:  Oncogene       Date:  2010-02-08       Impact factor: 9.867

4.  Cell-adhesion-disrupting action of interleukin 6 in human ductal breast carcinoma cells.

Authors:  I Tamm; T Kikuchi; I Cardinale; J G Krueger
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

Review 5.  Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer.

Authors:  Riley J Morrow; Nima Etemadi; Belinda Yeo; Matthias Ernst
Journal:  Mediators Inflamm       Date:  2017-05-14       Impact factor: 4.711

6.  Identification of Potential Key Genes and Pathways for Inflammatory Breast Cancer Based on GEO and TCGA Databases.

Authors:  Qing Lv; Yansong Liu; Hu Huang; Mingjie Zhu; Junqiang Wu; Dong Meng
Journal:  Onco Targets Ther       Date:  2020-06-12       Impact factor: 4.147

Review 7.  Interleukin-6 at the Host-Tumor Interface: STAT3 in Biomolecular Condensates in Cancer Cells.

Authors:  Pravin B Sehgal
Journal:  Cells       Date:  2022-03-30       Impact factor: 6.600

8.  Induction by interleukin-6 of interferon regulatory factor 1 (IRF-1) gene expression through the palindromic interferon response element pIRE and cell type-dependent control of IRF-1 binding to DNA.

Authors:  S Harroch; M Revel; J Chebath
Journal:  EMBO J       Date:  1994-04-15       Impact factor: 11.598

9.  Protein‑ and growth‑modulatory effects of carcinoma‑associated fibroblasts on breast cancer cells: Role of interleukin‑6.

Authors:  Angela Dittmer; Theresia Lange; Benjamin Leyh; Jürgen Dittmer
Journal:  Int J Oncol       Date:  2019-11-22       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.